전신치료 후 장기간 종양의 유지를 보이는 전이성 유방암 환자의 임상적 특징
Factors Associated with Metastatic Breast Cancer in Patients Who Show Long-Term Stable Disease Status
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to analyze the basic clinical characteristics and survival of patients with breast cancer whose disease had been stably maintained for more than 24 months after systemic therapy. Methods: We retrospectively reviewed the medical records of patients with primary breast cancer who underwent surgery. Among these patients, patients with stage IV disease at diagnosis or those who developed distant metastasis during the follow-up period after surgery were included in this analysis. Patients whose disease remained stable for more than 24 months were classified as the long-term stable disease group. The remaining patients were classified as the control group. Results: A total of 245 patients were eligible for this analysis. Patients in the long-term stable disease group showed a lower rate of histologic type III, a higher rate of hormone receptor positivity, and received less adjuvant chemotherapy. In the long-term stable disease group, the most frequent site of metastasis was the lungs, whereas in the control group, it was the bones. Overall survival was significantly better in the long-term stable disease group than in the control group (p<0.001). In univariate analysis, factors affecting the overall survival rate were the duration from diagnosis to metastasis, the absence of lymphatic infiltration, and the presence of hormone receptors. In multivariate analysis, the duration from diagnosis to metastasis and the absence of lymphatic infiltration were significant factors affecting the overall survival rate. Conclusion: Disease progression was observed in many patients even after the disease had been stable for more than 24 months after systemic therapy. Although these patients had better outcomes compared with the others, continuous observation and possible additional treatment might be helpful for some patients.
Abstract
Purpose: This study aimed to analyze the basic clinical characteristics and survival of patients with breast cancer whose disease had been stably maintained for more than 24 months after systemic therapy. Methods: We retrospectively reviewed the medical records of patients with primary breast cancer who underwent surgery. Among these patients, patients with stage IV disease at diagnosis or those who developed distant metastasis during the follow-up period after surgery were included in this analysis. Patients whose disease remained stable for more than 24 months were classified as the long-term stable disease group. The remaining patients were classified as the control group. Results: A total of 245 patients were eligible for this analysis. Patients in the long-term stable disease group showed a lower rate of histologic type III, a higher rate of hormone receptor positivity, and received less adjuvant chemotherapy. In the long-term stable disease group, the most frequent site of metastasis was the lungs, whereas in the control group, it was the bones. Overall survival was significantly better in the long-term stable disease group than in the control group (p<0.001). In univariate analysis, factors affecting the overall survival rate were the duration from diagnosis to metastasis, the absence of lymphatic infiltration, and the presence of hormone receptors. In multivariate analysis, the duration from diagnosis to metastasis and the absence of lymphatic infiltration were significant factors affecting the overall survival rate. Conclusion: Disease progression was observed in many patients even after the disease had been stable for more than 24 months after systemic therapy. Although these patients had better outcomes compared with the others, continuous observation and possible additional treatment might be helpful for some patients.
참고문헌 (22)
- Andre F, "Breast cancer with synchronous metastases: trends in survival during a 14-year period", J Clin Oncol, 22, pp.3302~3308 (2004)
- Bayraktar S, "Surviving metastatic breast cancer for 18 years: a case report and review of the literature", Breast J, 17, pp.521~524 (2011)
- Cardoso F, "Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?", Ann Oncol, 13, pp.197~207 (2002)
- Azim HA Jr, "Long-term toxic effects of adjuvant chemotherapy in breast cancer", Ann Oncol, 22, pp.1939~1947 (2011)
- Dufresne A, "Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer", Int J Med Sci, 5, pp.100~105 (2008)
- Early Breast Cancer Trialists’ Collaborative Group, "Tamoxifen for early breast cancer: an overview of the randomised trials", Lancet, 351, pp.1451~1467 (1998)
- Fossati R, "Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women", J Clin Oncol, 16, pp.3439~3460 (1998)
- Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N Engl J Med, 344, pp.783~792 (2001)
- Baselga J, "Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer", J Clin Oncol, 27, pp.2630~2637 (2009)
- Baselga J, "Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer", N Engl J Med, 366, pp.520~529 (2012)
- Cardoso F, "Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 23(7), pp.11~19 (2012)
- 류동원, "Impact of Serum HER2 Levels on Survival and Its Correlation with Clinicopathological Parameters in Women with Breast Cancer", Journal of Breast Cancer, 15(1), pp.71~78 (2012), 한국유방암학회
- Dunnwald LK, "Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients", Breast Cancer Res, 9, pp.R6~ (2007)
- Thorat MA, "Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis", J Clin Pathol, 61, pp.327~332 (2008)
- Solomayer EF, "Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis", Breast Cancer Res Treat, 59, pp.271~278 (2000)
- Patanaphan V, "Breast cancer: metastatic patterns and their prognosis", South Med J, 81, pp.1109~1112 (1988)
- Cristofanilli M, "Circulating tumor cells, disease progression, and survival in metastatic breast cancer", N Engl J Med, 351, pp.781~791 (2004)
- Gerratana L, "Pattern of metastasis and outcome in patients with breast cancer", Clin Exp Metastasis, 32, pp.125~133 (2015)
- Wang H, "The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study", Oncotarget, 8, pp.26368~26379 (2017)
- Dieter Hölzel, "Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry", Journal of Cancer Research and Clinical Oncology, 143(9), pp.1701~1712 (2017), Springer Nature[DOI]
- Shapiro CL, "Side effects of adjuvant treatment of breast cancer", N Engl J Med, 344, pp.1997~2008 (2001)
- Coates A, "On the receiving end: patient perception of the side-effects of cancer chemotherapy", Eur J Cancer Clin Oncol, 19, pp.203~208 (1983)